A double‐blind, placebo‐controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.

Mckee, P. J. W.; Blacklaw, J.; Forrest, Gerard; Gillham, R. A.; Walker, Stephen; Connelly, Diana; Brodie, Martin J.

doi:10.1111/j.1365-2125.1994.tb04234.x

Cited by 108 publications

(46 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If CBZ is discontinued from coadministration with LTG, the plasma concentration of LTG can be expected to increase (59,60). A similar effect is seen with TGB and OCBZ after the discontinuation of coadministered CBZ (61).…”

Section: Vpa Ltg Tpm Tgb and Oxc Coadministered With Enzyme-inducsupporting

confidence: 58%

The Importance of Drug Interactions in Epilepsy Therapy

et al. 2002

View full text Add to dashboard Cite

Summary: Long-term antiepileptic drug (AED) therapy is the reality for the majority of patients diagnosed with epilepsy. One AED will usually be sufficient to control seizures effectively, but a significant proportion of patients will need to receive a multiple AED regimen. Furthermore, polytherapy may be necessary for the treatment of concomitant disease. The fact that over-the-counter drugs and nutritional supplements are increasingly being self-administered by patients also must be considered. Therefore the probability of patients with epilepsy experiencing drug interactions is high, particularly with the traditional AEDs, which are highly prone to drug interactions. Physicians prescribing AEDs to patients with epilepsy must, therefore, be aware of the potential for drug interactions and the effects (pharmacokinetic and pharmacodynamic) that can occur both during combination therapy and on drug discontinuation. Although pharmacokinetic interactions are numerous and well described, pharmacodynamic interactions are few and usually concluded by default. Perhaps the most clinically significant pharmacodynamic interaction is that of lamotrigine (LTG) and valproic acid (VPA); these drugs exhibit synergistic efficacy when coadministered in patients with refractory partial and generalised seizures. Hepatic metabolism is often the target for pharmacokinetic drug interactions, and enzyme-inducing drugs such as phenytoin (PHT), phenobarbitone (PB), and carbamazepine (CBZ) will readily enhance the metabolism of other AEDs [e.g., LTG, topiramate (TPM), and tiagabine (TGB)].The enzyme-inducing AEDs also enhance the metabolism of many other drugs (e.g., oral contraceptives, antidepressants, and warfarin) so that therapeutic efficacy of coadministered drugs is lost unless the dosage is increased. VPA inhibits the metabolism of PB and LTG, resulting in an elevation in the plasma concentrations of the inhibited drugs and consequently an increased risk of toxicity. The inhibition of the metabolism of CBZ by VPA results in an elevation of the metabolite CBZepoxide, which also increases the risk of toxicity. Other examples include the inhibition of PHT and CBZ metabolism by cimetidine and CBZ metabolism by erythromycin. In recent years, a more rational approach has been taken with regard to metabolic drug interactions because of our enhanced understanding of the cytochrome P450 system that is responsible for the metabolism of many drugs, including AEDs. The review briefly discusses the mechanisms of drug interactions and then proceeds to highlight some of the more clinically relevant drug interactions between AEDs and between AEDs and non-AEDs. Understanding the fundamental principles that contribute to a drug interaction may help the physician to better anticipate a drug interaction and allow a graded and planned therapeutic response and, therefore, help to enhance the management of patients with epilepsy who may require treatment with polytherapy regimens.

show abstract

Section: Vpa Ltg Tpm Tgb and Oxc Coadministered With Enzyme-inducsupporting

confidence: 58%

The Importance of Drug Interactions in Epilepsy Therapy

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Tartara et al [20] reported that the metabolism of OXC (600 mg single dose) was induced approximately 30% by PB, as demonstrated by a lower plasma concentration of MHD. McKee et al [22] found that CBZ and PHT decreased the AUC of MHD by 40% and 29%, respectively. In previous population pharmacokinetic modeling studies [2,3,23] , CBZ, PB, or PHT administered with OXC increased the apparent clearance of the MHD metabolite by 31% to 75%.…”

Section: Discussionmentioning

confidence: 99%

“…As an inhibitor of UGT enzymes, VPA has been shown to have a potent inhibiting effect on the glucuronidation of LTG [2] . Although OXC is also primarily cleared by glucuronic acid conjugation, the majority of studies [20,22] found there were no drug-drug interactions for VPA used with OXC. Tartara et al [20] suggested that the glucuronyl transferase isozymes catalyzing MHD conjugation differ from those responsible for the glucuronidation of LTG.…”

Section: P<005)mentioning

confidence: 99%

Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy

et al. 2014

View full text Add to dashboard Cite

Aim: To develop a population pharmacokinetics model of oxcarbazepine in Chinese pediatric patients with epilepsy, and to study the interactions between oxcarbazepine and other antiepileptic drugs (AEDs). Methods: A total of 688 patients with epilepsy aged 2 months to 18 years were divided into model (n=573) and valid (n=115) groups. Serum concentrations of the main active metabolite of oxcarbazepine, 10-hydroxycarbazepine (MHD), were determined 0.5-48 h after the last dosage. A population pharmacokinetics (PPK) model was constructed using NLME software. This model was internally evaluated using Bootstrapping and goodness-of-fit plots inspection. The data of the valid group were used to calculate the mean prediction error (MPE), mean absolute prediction error (MAE), mean squared prediction error (MSE) and the 95% confidence intervals (95% CI) to externally evaluate the model.

show abstract

“…Strong enzyme-inducers such as carbamazepine, phenytoin or phenobarbital are known to decrease the serum concentration of MHD by 13% -40% [4][5][6][7].…”

Section: To the Editorsmentioning

confidence: 99%